Keywords: Lexicon Pharma. M&A, Symphony Icon, Gastrointestingal products
Lexicon Pharma acquires Symphony Icon, obtaining rights to gastrointestinal drugs for up to $90 million
Article | 03 August 2010
US biopharmaceutical company Lexicon Pharmaceuticals revealed yesterday that it has bought Symphony Icon, thus reacquiring rights to several developing gastrointestinal ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- AstraZeneca plans to move three cancer drug candidates into Ph III
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Merck Serono Ph III trial of L-BLP25 fails endpoint in NSCLC
